Reapplix Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $22.6M

  • Investors
  • 10

Reapplix General Information

Description

Manufacturer of a tissue regeneration device designed to offer biological treatment and management of diabetic foot ulcers. The company offers evidence-based biological wound therapy made entirely from the patient's blood to accelerate the healing of hard-to-heal diabetic foot ulcers, enabling hospitals to provide autologous active cell therapy to their patients to improve healing outcomes while reducing treatment costs.

Contact Information

Website
www.reapplix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bregnerødvej 133A
  • 3460 Birkerod
  • Denmark
+45 88
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Vertical(s)
Life Sciences
Corporate Office
  • Bregnerødvej 133A
  • 3460 Birkerod
  • Denmark
+45 88

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reapplix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 13-Jul-2020 $22.6M Completed Generating Revenue
6. Later Stage VC 23-Oct-2019 Completed Generating Revenue
5. Later Stage VC 31-Dec-2018 Completed Generating Revenue
4. Later Stage VC 27-Sep-2016 Completed Generating Revenue
3. Early Stage VC 21-Dec-2012 Completed Generating Revenue
2. Early Stage VC 02-Sep-2010 $2M $2.51M Completed Generating Revenue
1. Seed Round 01-Mar-2010 $508K $508K Completed Startup
To view Reapplix’s complete valuation and funding history, request access »

Reapplix Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
D shares
C shares 145,000 $12.08 $12.08 1x $12.08 2.7%
B shares 98,930 $4.23 $4.23 1x $4.23 1.84%
To view Reapplix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Reapplix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of a tissue regeneration device designed to offer biological treatment and management of diabetic foot ulce
Therapeutic Devices
Birkerod, Denmark
31 As of 2025

Mont-Saint-Guibert, Belgium
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reapplix Competitors (6)

One of Reapplix’s 6 competitors is NOVADIP, a Venture Capital-Backed company based in Mont-Saint-Guibert, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NOVADIP Venture Capital-Backed Mont-Saint-Guibert, Belgium
Podimetrics Venture Capital-Backed Somerville, MA
Amnio Technology Accelerator/Incubator Backed Phoenix, AZ
Mölnlycke Health Care Private Equity-Backed Mölndal, Sweden
Globus Medical Formerly VC-backed Audubon, PA
To view Reapplix’s complete competitors history, request access »

Reapplix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reapplix Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Lauxera Capital Partners Growth/Expansion Minority
MK Ventures Venture Capital Minority
North East Health Care Corporation Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Reapplix FAQs

  • When was Reapplix founded?

    Reapplix was founded in 2008.

  • Where is Reapplix headquartered?

    Reapplix is headquartered in Birkerod, Denmark.

  • What is the size of Reapplix?

    Reapplix has 31 total employees.

  • What industry is Reapplix in?

    Reapplix’s primary industry is Therapeutic Devices.

  • Is Reapplix a private or public company?

    Reapplix is a Private company.

  • What is the current valuation of Reapplix?

    The current valuation of Reapplix is .

  • What is Reapplix’s current revenue?

    The current revenue for Reapplix is .

  • How much funding has Reapplix raised over time?

    Reapplix has raised $48M.

  • Who are Reapplix’s investors?

    , , Lauxera Capital Partners, MK Ventures, and North East Health Care are 5 of 10 investors who have invested in Reapplix.

  • Who are Reapplix’s competitors?

    NOVADIP, Podimetrics, Amnio Technology, Mölnlycke Health Care, and Globus Medical are some of the 6 competitors of Reapplix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »